International collaboration is key for successful patient-centric drug repurposing and repositioning

REMEDi4ALL is an European Union-funded research initiative aimed to create a sustainable and globally connected platform and drive forward the repurposing of medicines across Europe. The REMEDi4ALL consortium (https://remedi4all.org/) brings together a unique combination of expertise to address the complexities of drug repurposing with capacities accessible to the research community. Led by EATRIS, the European Infrastructure for Translational Medicine (https://eatris.eu/), 24 organizations have joined forces to alleviate systemic bottlenecks in drug repurposing. REMEDi4ALL aims to construct an integrated platform encompassing advanced drug research facilities with clinical and translational research expertise, clinical operations, patient engagement methodologies, education & training, regulatory experts, health technology assessment, building a globally connected community of practice that will also include a network of funders. As a disease-agnostic and patient-centric platform, REMEDi4ALL has the potential to boost drug repurposing or repositioning of already approved, discontinued, shelved or investigational therapeutics by improving the ecosystem in Europe as well as globally. Its ultimate aim is to unlock the full potential drug repurposing by reducing development times and costs for new therapeutic opportunities for conditions with high unmet need. REMEDi4ALL launched in late 2022 with 4 initial drug repurposing projects in various development stages and addressing different challenges in drug repurposing (e.g., drug screening, reformulation, combination therapy and multinational clinical trials) and in different disease areas (e.g., oncology, infectious disease, ultra-rare genetic diseases). The philosophy of the platform is to work with multidisciplinary teams in a targeted and patient-centric manner and for each project to focus on the critical path to bring an existing drug substance or drug product through the approval process and into clinical practice.